Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703373 | 0.80 | NPC1 (0.56) | RAB9ANPC1MAPTLMNAKMT2A | |
| SCHEMBL1703648 | 0.78 | RAB9A (0.56) | RAB9ANPC1MAPTLMNAKMT2A | |
| SCHEMBL20303197 | 0.75 | MAPT (0.43) | RAB9ANPC1MAPTLMNAKMT2A | |
| SCHEMBL20838928 | 0.74 | ADORA1 (0.65) | RAB9ANPC1MAPT | |
| SCHEMBL633920 | 0.74 | RAB9A (0.59) | RAB9ANPC1MAPTLMNAKMT2A | |
| SCHEMBL24670696 | 0.73 | RAB9A (0.65) | RAB9ANPC1MAPTLMNAKMT2A | |
| SCHEMBL29803640 | 0.73 | RAB9A (0.65) | RAB9ANPC1MAPTLMNAKMT2A | |
| SCHEMBL1703428 | 0.73 | DHODH (0.51) | RAB9ANPC1MAPTLMNAKMT2A | |
| SCHEMBL1703768 | 0.73 | RAB9A (0.64) | RAB9ANPC1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4015806 | 0.73 | L3MBTL1 (0.50) | RAB9ANPC1MAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590328-B1 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7696225-B2 | (2-carboxamido)(3-Amino) thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7524859-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1590328-A4 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1807419-A1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060247275-A1 | (2-carboxamido)(3-amino)thiophene compounds | CREW ANDREW P | 2006-11-02 | — | — | US | disclosed |
| US-7101893-B2 | (2-Carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2006047574-A1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| EP-1590328-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6949563-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2005-09-27 | — | — | US | disclosed |
| US-20050192320-A1 | (2-Carboxamido)(3-amino)thiophene compounds | CREW ANDREW P (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050154014-A1 | (2-carboxamido)(3-amino) thiophene compounds | OSI PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20040186124-A1 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004063330-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186124-A1 | (2-carboxamido)(3-amino)thiophene compounds | ABL1, NAT1, KRAS | RAB9A 853/4885NPC1 1413/4885MAPT 3724/4885 |
| US-20050154014-A1 | (2-carboxamido)(3-amino) thiophene compounds | AADAC, PAM, TPMT | RAB9A 1825/4885NPC1 2915/4885MAPT 3429/4885 |
| US-20060247275-A1 | (2-carboxamido)(3-amino)thiophene compounds | PCNA, MKI67, MYC | RAB9A 2855/4885NPC1 913/4885MAPT 3594/4885 |
| US-20050192320-A1 | (2-Carboxamido)(3-amino)thiophene compounds | PCNA, MKI67, TPMT | RAB9A 2384/4885NPC1 991/4885MAPT 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.